Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial.
Interferon-α administration during structured treatment interruptions (STIs) was studied in a phase III trial. We randomized 168 chronically infected HIV undetectable under combined antiretroviral therapy patients to have three STIs with or without α-interferon. The number of patients who had to resume treatment during post-STI follow-up was not significantly different between the two arms. Patients with a low CD4 nadir and a high baseline HIV-DNA had a higher risk of treatment resumption in the interferon arm.
Boué
François
F
Hôpital Antoine Béclère APHP, Université Paris-Sud, Clamart, France. francois.boue@abc.aphp.fr
Reynes
Jacques
J
Rouzioux
Christine
C
Emilie
Dominique
D
Souala
Faouzi
F
Tubiana
Rolland
R
Goujard
Cécile
C
Lancar
Rémi
R
Costagliola
Dominique
D
D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes; D002908:Chronic Disease; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D019562:Viral Load
D044966:Anti-Retroviral Agents; D016898:Interferon-alpha